Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021
15 avr. 2021 08h15 HE
|
Chinook Therapeutics, Inc.
Poster presentation on BION-1301 including Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and 2 of the ongoing phase 1b study of BION-1301 and data from the phase 1 IV to SC bioavailability...
Chinook Therapeutics to Present at Upcoming Investor Conferences
08 avr. 2021 16h30 HE
|
Chinook Therapeutics, Inc.
SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
07 avr. 2021 16h05 HE
|
Chinook Therapeutics, Inc.
SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
07 avr. 2021 08h15 HE
|
Chinook Therapeutics, Inc.
Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022 SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a...
Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
05 avr. 2021 08h15 HE
|
Chinook Therapeutics, Inc.
Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs VANCOUVER, British Columbia and SEATTLE, April ...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2021 16h15 HE
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, April 01, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and...
Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress
30 mars 2021 16h26 HE
|
Chinook Therapeutics, Inc.
Key presentations for BION-1301 at the ISN World Congress of Nephrology 2021 in April include Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and Part 2 of the ongoing phase 1 study of...
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
16 mars 2021 08h15 HE
|
Chinook Therapeutics, Inc.
Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021 VANCOUVER, British Columbia and SEATTLE, March 16, 2021 (GLOBE...
Chinook Therapeutics to Present at Upcoming Investor Conferences
02 mars 2021 16h15 HE
|
Chinook Therapeutics, Inc.
VANCOUVER, British Columbia and SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and...
Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
01 mars 2021 08h15 HE
|
Chinook Therapeutics, Inc.
Collaboration will Leverage Access to the NURTuRE Patient Biobank and Evotec’s PanHunter Multi-Omics Platform to Characterize Molecular Drivers, Identify and Validate Novel Targets and Drive Patient...